Regeneron Pharmaceuticals, Inc. (REGN) - Gabelli Research Analyst Jing He (3-1-2018) Invest with Us 1-800-GABELLI (800-422-3554) http://facebook.com/gabellitv GabelliTV Transcript: Hi. My name is Jing He and I’m a biotech analyst at Gabelli. We are recommending a Buy on Regeneron Pharmaceuticals with a 2019 PMV of 442 dollars per share. The company has 115 million shares out, closed at $321, market cap $36.8 billion, net cash $2.9 billion and total enterprise value $33.9 billion. Recently, the shares are trading at near a 52-week low, due to concerns on competition of its key drug, Eylea. We believe Eylea will maintain its dominant position in retinal market. Novartis’ brolucizumab won’t enter the market until late 2019 and will initially compete only in the well-penetrated AMD market. The other competitor, Roche’s bispecific RG7716 needs to prove that its efficacy and safety in Phase 2 will hold in a larger and longer-term Phase 3 trial. Regeneron’s Dupixent had a strong launch in 2017 despite administrative hurdles from payers. We expect it to become a blockbuster drug in 2018, as Regeneron and partner Sanofi improve their commercial execution. Near-term catalysts include readout of Praluent’s outcomes trial in March, and ceMiplimab’s approval in mid-2018.
PRE-ORDER THE NEW DAVID GUETTA ALBUM NOW : https://davidguetta.lnk.to/Album7AY ⚠️ Vote David Guetta #1 on DJ Mag TOP 100 DJ : http://bit.ly/GuettaMag2018 Download the album #Listen and the single Hey Mama on iTunes http://smarturl.it/guettalistendeluxe Download the remixes on iTunes: http://smarturl.it/DavidGuettaHeyMama Download the remixes on Beatport: https://pro.beatport.com/release/hey-mama-remixes-ep/1527829 Including remixes by Afrojack, GLOWINTHEDARK, Noodles, Club Killers, Modern Machines, DJ LBR Download the TuneMoji® App for iPhone & send FREE music GIFs: http://bit.ly/TuneMoji1TuCWWR HEY MAMA (FEAT NICKI MINAJ, BEBE REXHA & AFROJACK) (David Guetta, Giorgio Tuinfort, Nick Van de Wall, Ester Dean, Bebe Rexha, Sean Douglas, Nicki Minaj) Produced by David Guetta, Afrojack & Giorgio Tuinfort. Co-Produced by Ester Dean Publishers: What A Publishing Ltd ; Piano Songs / BMG Talpa Music B.V. (BUMA) / Sony ATV (BMI) ; Warner-Tamerlane Publishing Corp. (BMI) & Eastman Pond Publishing (BMI) ; Damn Dat Music admin by Universal Music Publishing; BMG Platinum Songs/Kiss Me If You Can Music (BMI) All Rights Administered By BMG Rights Management (US) LLC ; DLG Publishing/BMG Talpa Music B.V.; O. Maraj Publishing Co: Harajuku Barbie Music/Money Mack Music/Songs of Universal, Inc.(BMI). All instruments & programming by David Guetta & Giorgio Tuinfort. Additional Instruments & Programming by Afrojack. Brass Arrangement : Jel Jongen & Giorgio Tuinfort. Brass : The Jay Horns. Trumpet : Serge Plume. Trombone : Jel Jongen. Recorded by Jel Jongen at Jay Sound Studio Hilversum, Netherlands & by Aubry «Big Juice» Delaine and Daniel Zaidenstadt at MSR studios NYC and EKAS studios Santa Monica, CA, assisted by Dan Fyfe and Todd Bergman. Vocals Engineers: Daniel Zaidenstadt, Ryan Gladieux. Vocals mixed by Rutger «Rutti» Kroese. Assisted by Jeremia Jones. Mixed by Afrojack & Rutger «Rutti» Kroese at Afrojack Studio’s Leersum, Netherlands & Cruise Control Studio’s Amsterdam, Netherlands. Nicki Minaj appears courtesy of Young Money Entertainment / Cash Money Records / Universal Motown records. Bebe Rexha appears courtesy of Warner Bros. Records Inc. (P) & (C) 2014 What A Music Ltd, Under Exclusive Licence to Parlophone/Warner Music France, a Warner Music Group Company http://www.davidguetta.com http://facebook.com/DavidGuetta http://www.twitter.com/DavidGuetta http://www.instagram.com/davidguetta
Here is what is going on with Antares Pharma, and why it will be a big long term winner
Gabelli Research analyst Jing He discusses her best idea for 2018, Incyte Corp. http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554) http://facebook.com/gabellitv GabelliTV Transcript: Hi. My name is Jing He and I’m a biotech analyst at Gabelli. We are highlighting Incyte as our top biotech pick with a 2018 PMV of 133 dollars per share. The company has 218 million shares out, trading at $94.58, equity market cap $20.6 billion, net cash $1.3 billion and total enterprise value $19.3 billion. Its key drug, Jakafi is on track to reach $2bn of sales in 2021 with potential label expansion in additional indications. We value the legacy franchise, including Jakafi and Iclusig at $17 billion. Incyte shares are trading at near a 52-week low, as if the entire pipeline with IDO, multiple early-stage candidates, plus baricitinib royalties, arguably the best oncology pipe, is worth only $2 billion. We believe its pipeline progress was given little credit, including the advancement of PD-1+ Epacadostat to multiple Phase 3 programs with Merck, Bristol and AstraZeneca, as well as positive Phase 1 data demonstrating 30% response rate in multiple tumor types with superior safety. Near-term catalysts include readout of Epacadostat+PD-1 in melanoma in the first half of 2018, and baricitinib’s approval in mid-2018.
form fill seal machine we made for kraft 5 kg of cheese fillng bag and then beeing dropt down to a carton. in this line we also made a carton erector in order to format the carton to a box.
ماكينه راسيه لتعبئه الصلصه والكاتشب لحام رباعى MULTILANE MACHINE 4VL تصنيع وتوريد الشركه الهندسيه للتكنولوجيا هايتك المنطقه الصناعيه الثانيه شارع 84 www.hitekeng.com 01114193456 مايكل عادل مدير التسويق 0238202179-178 0238202562 firstname.lastname@example.org
A Bug’s Death New Antibiotics for Superbugs - Gabelli Analyst Kevin Kedra (4-5-2018) http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554) http://facebook.com/gabellitv GabelliTV Transcript: The emergence of multi-drug resistant bacteria, or so-called superbugs, is becoming a global public health crisis. The CDC estimates that these superbugs infect 2 million Americans each year, leading to 23,000 deaths. New antibiotics are needed to treat these infections, and we expect to see an influx of potentially 6 new approvals over the next 18 months. Most of these upcoming approvals, along with the two approved in 2017, are coming from a handful of small biotech companies. These companies – Achaogen, Melinta Therapeutics, Motif Bio, Nabriva Therapeutics, Paratek Pharmaceuticals, and Tetraphase Pharmaceuticals – could see a wave of consolidation and deal activity that will leverage commercial infrastructures, extract cost synergies, and de-risk product portfolios with multiple antibiotics. Our favorite names in the antibiotic sector are Achaogen and Paratek. We expect both companies to gain FDA approval of their respective antibiotics, plazomicin and eravacycline, later this year, and believe that sales of each antibiotic could surpass $100 million by 2021. Achaogen trades at $13 per share, and we estimate a 2019 PMV of $18 per share. Paratek also trades at $13 per share and we estimate a 2019 PMV of $24 per share.
Material build-up in the pockets of a rotary valve can be a real problem. Don't stop production to clean it out. The PMDS combines rounded pockets with a scraper that sweep each pocket on every revolution.